CLAIMS

1. An agent for treating or preventing a cerebrovascular disorder,
wherein the agent comprises an HGF gene.

2. The agent of claim 1, wherein the cerebrovascular disorder is a
cerebral infarction.

3. The agent of claim 1 or 2, wherein the agent is in the form of
a tablet, pill, sugar-coated tablet, capsule, liquid, gel, ointment,
syrup, slurry, or suspension.

4. The agent of any one of claims 1 to 3, wherein the agent is used
to transfer a gene into a cell by a method employing a viral envelope
vector, internal type liposome, electrostatic type liposome,
HVJ-liposome, or improved HVJ-liposome, a receptor-mediated gene
transfer method, a method for transferring a nucleic acid molecule
along with a carrier into a cell by using a particle gun, a direct
introduction method using a naked-DNA, or an introduction method using
a cationic polymer.

5. The agent of any one of claims 1 to 3, wherein the agent is used
to transfer a gene into a cell by employing an HVJ-envelope.

6. A method for treating or preventing a cerebrovascular disorder,
wherein the method comprises the step of introducing an HGF gene into
a mammal.

7. The method of claim 6, wherein the cerebrovascular disorder is
a cerebral infarction.

8. The method of claim 6 or 7, wherein the method comprises the step
of introducing an HGF gene into a mammal two to three times by employing
an HVJ-envelope.

9. Use of an HGF gene to produce an agent for treating or preventing

a cerebrovascular disorder.

10. The use of the HGF gene of claim 9, wherein the cerebrovascular disorder is a cerebral infarction.

5